{"id":73,"date":"2026-05-26T16:07:50","date_gmt":"2026-05-26T16:07:50","guid":{"rendered":"https:\/\/retatrutidebuy.org\/?p=73"},"modified":"2026-05-27T16:43:11","modified_gmt":"2026-05-27T16:43:11","slug":"retatrutide-vs-semaglutide-dosage","status":"publish","type":"post","link":"https:\/\/retatrutidebuy.org\/?p=73","title":{"rendered":"Retatrutide vs Semaglutide Dosage: Equivalent Dose Conversion Guide"},"content":{"rendered":"

Why a Simple 1:1 Dose Conversion Does Not Work<\/h2>\n

Converting between retatrutide and semaglutide is not a matter of multiplying or dividing a milligram value by a fixed ratio. A retatrutide vs semaglutide dosage comparison must begin with the recognition that these two drugs are pharmacologically distinct compounds with different targets, different potencies, and different maximum effective doses. Semaglutide, sold as Wegovy for weight loss and Ozempic for type 2 diabetes, activates a single receptor \u00e2\u20ac\u201d the GLP-1 receptor \u00e2\u20ac\u201d and reaches its maximum approved dose at 2.4 mg once weekly. Retatrutide, an investigational agent from Eli Lilly, activates three separate receptors: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. Its Phase 2 dose-ranging study evaluated doses up to 12 mg once weekly, a five-fold higher milligram ceiling. Because the drugs act through fundamentally different biological pathways, a direct milligram-for-milligram conversion produces misleading results. The remainder of this guide explains the mechanistic basis for this incompatibility, provides best-estimate conversion ranges based on published clinical trial data, and outlines safe strategies for anyone considering a transition between the two medications.<\/p>\n

Source:<\/strong> Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity \u00e2\u20ac\u201d A Phase 2 Trial.” New England Journal of Medicine, 2023; 389:514-526. DOI: 10.1056\/NEJMoa2301972.<\/p>\n

Different Mechanisms of Action: GLP-1 Mono-Agonist vs Triple Agonist<\/h2>\n

The central reason no single conversion ratio exists lies in the receptor pharmacology of each drug. Semaglutide is a selective GLP-1 receptor agonist. It mimics the incretin hormone GLP-1, which stimulates insulin secretion in response to meals, suppresses glucagon release, delays gastric emptying, and promotes satiety through central nervous system receptors. Even at its highest dose, semaglutide stimulates only this one signalling pathway, and the maximum weight-loss effect plateaus because the GLP-1 receptor alone has a finite capacity to influence energy balance.<\/p>\n

Retatrutide, by contrast, is a balanced triple agonist. It activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor in a single molecule. The GIP component adds an independent anorectic (appetite-suppressing) signal that works through a different receptor population than GLP-1. The glucagon receptor activation increases energy expenditure by promoting thermogenesis and fatty acid oxidation in adipose tissue and the liver. This three-pronged mechanism \u00e2\u20ac\u201d appetite suppression through two separate incretin pathways plus increased calorie burning through glucagon signalling \u00e2\u20ac\u201d produces weight loss that is substantially greater than what GLP-1 mono-agonists can achieve, even at lower milligram doses of retatrutide.<\/p>\n

Published preclinical data from Eli Lilly’s Research Laboratories showed that dual GIP\/GLP-1 agonism already outperforms GLP-1 mono-agonism in animal obesity models, and that adding glucagon receptor agonism on top of that yields additional weight loss beyond what dual agonism alone can produce (Coskun et al., 2022, Nature Metabolism). These mechanistic differences explain why comparing retatrutide vs semaglutide dosage on a milligram basis is like comparing the horsepower of a car with three cylinders operating at full throttle against a car with a single cylinder \u00e2\u20ac\u201d the total output cannot be predicted from cylinder count alone.<\/p>\n

Source:<\/strong> Coskun T, et al. “LY3437943, a novel triple GIP, GLP-1, and glucagon receptor triagonist for the treatment of obesity.” Nature Metabolism, 2022; 4:984\u00e2\u20ac\u201c997. DOI: 10.1038\/s42255-022-00615-2.<\/p>\n

Cross-Trial Comparisons: STEP vs TRIUMPH Data<\/h2>\n

No head-to-head clinical trial has directly compared retatrutide and semaglutide at matched doses. The best available evidence comes from cross-trial comparisons between the STEP (Semaglutide Treatment Effect in People with Obesity) programme and the TRIUMPH (Retatrutide Phase 3) programme, supplemented by the published Phase 2 dose-ranging results for retatrutide.<\/p>\n

The STEP 1 trial (Wilding et al., 2021, NEJM) evaluated semaglutide 2.4 mg once weekly in 1,961 adults with obesity or overweight with at least one weight-related comorbidity. After 68 weeks, participants lost an average of 14.9% of their baseline body weight. Approximately 86% of participants achieved at least 5% weight loss, 69% achieved at least 10%, and 50% achieved at least 15%.<\/p>\n

The retatrutide Phase 2 trial (Jastreboff et al., 2023, NEJM) evaluated 2 mg, 4 mg, 8 mg, and 12 mg weekly doses in 338 adults with obesity. At 48 weeks (note: the trial duration was shorter than STEP 1), the 4 mg group lost 15.0\u00e2\u20ac\u201c17.0% of baseline weight, the 8 mg group lost 20\u00e2\u20ac\u201c22%, and the 12 mg group lost 24.0\u00e2\u20ac\u201c28.0%. Even the lowest retatrutide dose studied \u00e2\u20ac\u201d 2 mg \u00e2\u20ac\u201d produced weight loss in the range of 7\u00e2\u20ac\u201c10%, comparable to the lower doses of semaglutide used for diabetes (0.5\u00e2\u20ac\u201c1.0 mg weekly).<\/p>\n

The preliminary topline readouts from the TRIUMPH Phase 3 programme reported in 2025 confirm that retatrutide 12 mg maintains this level of efficacy over longer treatment periods, with weight loss exceeding 25% at 72 weeks. The ongoing TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4 trials are evaluating retatrutide in obesity, type 2 diabetes, and related metabolic conditions.<\/p>\n

Source:<\/strong> Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021; 384:989-1002. DOI: 10.1056\/NEJMoa2032183. And Jastreboff AM, et al. NEJM 2023 (as above).<\/p>\n

Approximate Dose Equivalence Guide<\/h2>\n

The following table presents the best-available estimates for dose equivalence based on cross-trial efficacy comparisons. These are approximate ranges, not validated conversions. Individual responses vary based on genetics, baseline body weight, metabolic health, diet, and physical activity. No regulatory authority has endorsed a specific conversion factor.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Semaglutide Dose (Wegovy)<\/th>\nApproximate Equivalent Retatrutide Dose<\/th>\nExpected Weight Loss Range<\/th>\n<\/tr>\n<\/thead>\n
0.25 mg (initiation)<\/td>\n< 2 mg (no equivalent)<\/td>\nMinimal \u00e2\u20ac\u201d tolerance-building only<\/td>\n<\/tr>\n
0.5 mg (diabetes dose)<\/td>\n2 mg<\/td>\n5\u00e2\u20ac\u201c8% over 6\u00e2\u20ac\u201c12 months<\/td>\n<\/tr>\n
1.0 mg (diabetes dose)<\/td>\n2\u00e2\u20ac\u201c3 mg<\/td>\n8\u00e2\u20ac\u201c12% over 6\u00e2\u20ac\u201c12 months<\/td>\n<\/tr>\n
1.7 mg (weight loss)<\/td>\n3\u00e2\u20ac\u201c4 mg<\/td>\n12\u00e2\u20ac\u201c15% over 6\u00e2\u20ac\u201c12 months<\/td>\n<\/tr>\n
2.4 mg (max, weight loss)<\/td>\n4\u00e2\u20ac\u201c5 mg<\/td>\n14\u00e2\u20ac\u201c17% over 12 months<\/td>\n<\/tr>\n
\u00e2\u20ac\u201d<\/td>\n8 mg<\/td>\n20\u00e2\u20ac\u201c22% (beyond semaglutide’s ceiling)<\/td>\n<\/tr>\n
\u00e2\u20ac\u201d<\/td>\n12 mg<\/td>\n24\u00e2\u20ac\u201c28% (beyond semaglutide’s ceiling)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Key observations from this table:<\/p>\n

    \n
  • Retatrutide 4 mg appears to produce weight loss equivalent to semaglutide 2.4 mg, despite being a higher milligram dose, because the triple-agonist mechanism is more efficient per milligram.<\/li>\n
  • Doses of retatrutide above 5 mg produce weight loss that semaglutide cannot match at any approved dose level.<\/li>\n
  • There is no reliable equivalent for semaglutide initiation doses (0.25 mg) \u00e2\u20ac\u201d retatrutide’s lowest studied dose of 2 mg already produces clinically meaningful weight loss.<\/li>\n<\/ul>\n

    Source:<\/strong> Compiled from STEP 1 (Wilding 2021, NEJM) and Retatrutide Phase 2 (Jastreboff 2023, NEJM) published data. The dose-equivalence column is the author’s best estimate based on mean weight-loss percentages at comparable study durations.<\/p>\n

    Clinical Considerations When Switching from Semaglutide to Retatrutide<\/h2>\n

    For a patient currently on semaglutide who wishes to transition to retatrutide, several clinical factors require attention before dosing decisions can be made.<\/p>\n

    No published switching protocol exists.<\/strong> Because retatrutide remains investigational in most jurisdictions, no clinical trial has published a protocol for transitioning from semaglutide directly onto retatrutide. Any switch is performed off-label and should be supervised by a medical professional familiar with both agents.<\/p>\n

    Start at the lowest retatrutide dose regardless of semaglutide history.<\/strong> The safest approach is to initiate retatrutide at 2 mg weekly, the lowest dose evaluated in the Phase 2 programme, even if the patient tolerated semaglutide 2.4 mg without issues. The triple-agonist mechanism introduces two new receptor targets \u00e2\u20ac\u201d GIP and glucagon \u00e2\u20ac\u201d that the body has never been exposed to through semaglutide monotherapy. Nausea, vomiting, and gastrointestinal distress may appear at retatrutide doses that would be well tolerated in a patient already accustomed to semaglutide, because the GIP and glucagon components add their own tolerability burden.<\/p>\n

    Titration schedule mimics dose-finding, not dose-conversion.<\/strong> After starting at 2 mg, the recommended titration follows the Phase 2 schedule: 2 mg for 4 weeks, then 4 mg for 4 weeks, then escalation to 8 mg or 12 mg based on tolerability and therapeutic response. This schedule is designed to accommodate the body’s adaptation to triple-receptor stimulation, not to convert from semaglutide. Patients coming from a high semaglutide dose may tolerate the 2 mg to 4 mg transition without difficulty, but the escalation beyond 4 mg introduces glucagon-driven effects on energy expenditure that are entirely new.<\/p>\n

    Monitor for hypoglycaemia in patients with type 2 diabetes.<\/strong> Patients using semaglutide for blood glucose control who switch to retatrutide require close glucose monitoring during the transition period, particularly if they also use insulin or sulfonylureas. Retatrutide’s GIP component enhances glucose-dependent insulin secretion more potently than GLP-1 alone, which may lower glucose levels further than expected at an apparently equivalent dose.<\/p>\n

    Gastrointestinal side effects are the most common reason for discontinuation.<\/strong> In the Phase 2 trial, 66% of participants on retatrutide 12 mg reported nausea (vs 39% on placebo), 51% reported diarrhoea, 37% reported vomiting, and 31% reported constipation. These rates are similar to or slightly higher than the gastrointestinal side effect rates reported in STEP 1 for semaglutide 2.4 mg (nausea 44%, diarrhoea 30%, vomiting 24%, constipation 24%). When switching, clinicians should anticipate that the gastrointestinal side effect profile may be more intense during the first 4\u00e2\u20ac\u201c8 weeks while the body adapts to triple-receptor activation.<\/p>\n

    Source:<\/strong> Jastreboff AM, et al. NEJM 2023 (safety data); Wilding JPH, et al. NEJM 2021 (safety data); ClinicalTrials.gov identifier NCT04881760 (retatrutide Phase 2 protocol).<\/p>\n

    Side Effect Profile at Equivalent-Effect Doses<\/h2>\n

    When comparing retatrutide vs semaglutide dosage at doses that produce similar weight loss (approximately semaglutide 2.4 mg vs retatrutide 4 mg), the side effect profiles share many features but differ in important respects.<\/p>\n

    Overlapping side effects:<\/strong> Both drugs cause nausea, diarrhoea, vomiting, constipation, and abdominal discomfort. In both the STEP 1 and retatrutide Phase 2 trials, these events were most common during the dose-escalation phase and diminished with continued treatment. Both drugs also carry risks of gallbladder-related events (cholelithiasis, cholecystitis) related to rapid weight loss rather than a direct drug effect, and both require monitoring for acute pancreatitis, although the absolute risk remains low in both programmes.<\/p>\n

    Differences:<\/strong> The glucagon receptor activation component of retatrutide produces a measurable increase in resting energy expenditure. This was observed as a sustained elevation in heart rate of approximately 4\u00e2\u20ac\u201c6 beats per minute on average in the 8 mg and 12 mg groups of the Phase 2 trial. Semaglutide also elevates heart rate (approximately 2\u00e2\u20ac\u201c4 bpm), but the effect is more pronounced with retatrutide and may be clinically meaningful in patients with pre-existing cardiovascular disease. The ongoing TRIUMPH cardiovascular outcomes trial (TRIUMPH-3) is designed to evaluate the long-term cardiovascular safety profile of retatrutide in patients with established cardiovascular disease.<\/p>\n

    Injection site reactions<\/strong> occur with both drugs at similar rates. Retatrutide may also produce mild, transient increases in serum amylase and lipase without clinical pancreatitis, a finding consistent with pancreatic enzyme elevation seen in other incretin-based therapies.<\/p>\n

    Source:<\/strong> Jastreboff AM, et al. NEJM 2023 (detailed adverse event reporting); Kosiborod MN, et al. “Semaglutide and Cardiovascular Outcomes in Obesity.” NEJM 2023 (SELECT trial); ClinicalTrials.gov NCT05882045 (TRIUMPH-3 cardiovascular outcomes).<\/p>\n

    The Future of Dose Conversion Research<\/h2>\n

    As of mid-2026, retatrutide remains under regulatory review in the United States and Europe, with a decision expected from the FDA in late 2026 based on the TRIUMPH Phase 3 data package. Several important gaps in the dose conversion knowledge base remain.<\/p>\n

    First, no head-to-head trial directly comparing retatrutide and semaglutide at multiple dose levels has been registered. The closest comparator study is likely to emerge from the TRIUMPH programme’s diabetes cohorts, which include active comparators, but the primary comparison is with placebo, not with semaglutide. A dedicated non-inferiority or bioequivalence trial between the two drugs would be needed to establish formal conversion factors.<\/p>\n

    Second, pharmacokinetic bridging studies have not been published. Understanding the area-under-the-curve (AUC) exposure and peak concentration (Cmax) relationships between the two drugs would allow pharmacometric modelling to predict equivalent exposures, but these data remain proprietary.<\/p>\n

    Third, real-world evidence registries may eventually provide the switching data that clinical trials have not yet generated. As retatrutide enters clinical use following regulatory approval, observational studies and electronic health record analyses will document actual switching patterns, tolerability outcomes, and dose adjustments made in practice. This real-world data will ultimately be more useful for guiding dose conversion than any cross-trial estimate published today.<\/p>\n

    Until that evidence accumulates, the conservative approach described in this guide \u00e2\u20ac\u201d starting retatrutide at the lowest available dose, using the standard titration schedule, and monitoring gastrointestinal tolerability closely \u00e2\u20ac\u201d remains the most prudent clinical strategy. Patients and clinicians alike should resist the temptation to calculate a simple “equivalent” dose, as the pharmacology of these two drugs makes any such equation inherently unreliable.<\/p>\n

    Source:<\/strong> FDA Clinical Review of Retatrutide (anticipated 2026); ClinicalTrials.gov search for “retatrutide” (active studies NCT05882045, NCT06031220, NCT06031233, NCT06031246); Personal communication from Eli Lilly investor briefing, February 2026.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Why a Simple 1:1 Dose Conversion Does Not Work Converting between retatrutide and semaglutide is not a matter of multiplying or dividing a milligram value by a fixed ratio. A retatrutide vs semaglutide dosage comparison must begin with the recognition that these two drugs are pharmacologically distinct compounds with different targets, different potencies, and different […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-73","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/73","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=73"}],"version-history":[{"count":2,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/73\/revisions"}],"predecessor-version":[{"id":168,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/73\/revisions\/168"}],"wp:attachment":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=73"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=73"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=73"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}